ClinicalTrials.gov
public full text
Public Domain
A Phase 2 Study of Recombinant Anti-IL-17A Humanized Monoclonal Antibody in Chinese Participants With Moderate-to-Severe Plaque Psoriasis
The purpose of this study is to determine the efficacy and safety of the study drug recombinant anti-IL-17A humanized monoclonal antibody in Chinese participants with moderate-to-severe plaque psoriasis.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Vunakizumab for the Treatment of Mild to Moderate Systemic Lupus Erythematosus#970048
- Current and Emerging Therapies Targeting the IL-23/IL-17 Axis in Psoriasis.#161918
- A Study to Evaluate Efficacy and Safety of SAR441566 in Adults With Plaque Psoriasis#859918
- eGPA and Local Inflammation Within the Ear, Nose and Throat Area#1282636
- Interleukin-31 targeting and other novel drugs in itch / Péter Oláh, Bernhard Homey, Ulrike Raap#1214931
Record · ID 1476679
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive